Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent 125iodine implants-Reference-Cited by-同舟云学术

Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent 125iodine implants

Published:2010-01-08 Issue:1 Volume:106 Page:32-36
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:

Author:

Prada Pedro J.,Juan Germán,González-Suárez Herminio,Fernández José,Jimenez Isabel,Amón José,Cepeda Marcos

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2009.09096.x/fullpdf

Reference28 articles.

1. The National cancer data base report on increase use of brachytherapy for the treatment of patients with prostate carcinoma in the USA;Mettlin;Cancer,1999

2. The 1999 Patterns of care Study of radiotherapy in localized prostatic carcinoma. A comprehensive survey of prostate brachytherapy in the United States;Lee;Cancer,2003

3. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer;Ash;Radiother Oncol,2000

4. Results of permanent prostate brachytherapy, 13 years of experience at a single institution;Battermann;Radiother Oncol,2004

5. Conformal prostate brachytherapy guided by real-time dynamic dose calculation in permanent I-125 implants. Technical description and preliminary experience;Prada;Arch Esp Urol,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Trend of Radiation Therapy for Patients with Localized Prostate Cancer;Current Oncology;2023-09-01

2. Biochemical outcomes and toxicities in young men with prostate cancer after permanent iodine-125 seed implantation: Prospective cohort study in 6662 patients;Brachytherapy;2023-05

3. Acute and late side-effects after low dose-rate brachytherapy for prostate cancer; incidence, management and technical considerations;Brachytherapy;2021-09

4. Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival;Journal of Contemporary Brachytherapy;2021

5. Permanent seed implant brachytherapy in low-risk prostate cancer: Preoperative planning with 145 Gy versus real-time intraoperative planning with 160 Gy;Reports of Practical Oncology & Radiotherapy;2018-07